Lupus anticoagulants, thrombosis and the protein C system

Haematologica

Volumn 84, Issue 5, 1999, Pages 446-451

  Esmon, Naomi L ^a,b,d   Smirnov, Mikhail D ^a   Safa, Omid ^a   Esmon, Charles T ^a,b,c  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d Research Program   (United States)

Author keywords

Lupus anticoagulant; Protein C system; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 5A; LUPUS ANTICOAGULANT; PROTEIN C; PROTEIN S;

ANTICOAGULATION; ANTIGEN BINDING; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHIMERA; HUMAN; PROTEIN CONFORMATION; PROTEIN DETERMINATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; STRUCTURE ACTIVITY RELATION; THROMBOSIS;

HUMANS; LUPUS COAGULATION INHIBITOR; PROTEIN C; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBOSIS;

EID: 0032823271     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Carreras LO, Forastiero RR. Pathogenic role of antiprotein-phospholipid antibodies. Haemostasis 1996; 26(Suppl. 4):340-57.
2. Triplett DA. Antiphospholipid antibodies and thrombosis. A consequence, coincidence, or cause? Arch Pathol Lab Med 1993; 117:78-88.
3. Roubey RAS. Autoantibodies to phospholipid-binding plasma proteins: A new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. Blood 1994; 84:2854-67.
4. Esmon CT, Schwarz HP. An update on clinical and basic aspects of the protein C anticoagulant pathway. Trends Cardiovasc Med 1995; 5:141-8.
5. Smirnov MD, Triplett DT, Comp PC, Esmon NL, Esmon CT. On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J Clin Invest 1995; 95: 309-16.
6. Oosting JD, Derksen RHWM, Bobbink IWG, Hackeng TM, Bouma BN, de Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood 1993; 81:2618-25.
7. Bokarewa MI, Blomback M, Egberg N, Rosen S. A new variant of interaction between phospholipid antibodies and the protein C system. Blood Coagul Fibrinol 1994; 5:37-41.
8. Mann KG, Krishnaswamy S, Lawson JH. Surface-dependent hemostasis. Semin Hematol 1992; 29: 213-26.
9. Berrard M, Boffa MC, Karmochkine M, et al. Plasma reactivity to hexagonal II phase phosphatidylethanolamine is more frequently associated with lupus anticoagulant than with antiphosphatidylethanolamine antibodies. J Lab Clin Med 1993; 122:601-5.
10. Karmochkine M, Cacoub P, Piette JC, Godeau P, Boffa MC. Antiphosphatidylethanolamine antibody as the sole antiphospholipid antibody in systemic lupus erythematosus with thrombosis. Clin Exp Rheumatol 1992; 10:603-5.
11. Berard M, Chantome R, Marcelli A, Boffa M-C. Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies. I. Association with thrombosis and vascular cutaneous diseases. J Rheumatol 1996; 23:1369-74.
12. Sugi T, McIntyre JA. Phosphatidylethanolamine induces specific conformational changes in the kininogens recognizable by antiphosphatidylethanolamine antibodies. Thromb Haemost 1996; 76:354-60.
13. Smirnov MD, Esmon CT. Phosphatidylethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated protein C. J Biol Chem 1994; 269:816-9.
14. Esmon NL, Smirnov MD, Esmon CT. Lupus anticoagulants and thrombosis: the role of phospholipids. Haematologica 1997; 78:70-4.
15. Smeets EF, Comfurius P, Bevers EM, Zwaal RFA. Contribution of different phospholipid classes to the prothrombin converting capacity of sonicated lipid vesicles. Thromb Res 1996; 81:419-26.
16. Esmon NL, Smirnov MD, Esmon CT. Thrombogenic mechanisms of antiphospholipid antibodies. Thromb Haemostas 1997; 78:79-82.
17. Neuenschwander PF, Bianco-Fisher E, Rezaie AR, Morrissey JH. Phosphatidylethanolamine augments factor VIIa-tissue factor activity: enhancement of sensitivity to phosphatidylserine. Biochemistry 1995; 34:13988-93.
18. Gilbert GE, Arena AA. Phosphatidylethanolamine induces high affinity binding sites for factor VIII on membranes containing phosphatidyl-L-serine. J Biol Chem 1995; 270:18500-5.
19. Rauch J, Tannenbaum M, Tannenbaum H, et al. Human hybridoma lupus anticoagulants distinguish between lamellar and hexagonal phase lipid systems. J Biol Chem 1986; 261:9672-7.
20. Higgins DL, Callahan PJ, Prendergast FG, Nesheim ME, Mann KG. Lipid mobility in the assembly and expression of the activity of the prothrombinase complex. J Biol Chem 1985; 260:3604-12.
21. Govers-Riemslag JWP, Janssen MP, Zwaal RFA, Rosing J. Prothrombin activation on dioleoylphosphatidylcholine membranes. Eur J Biochem 1994; 220:131-8.
22. Furie B, Diuguid CF, Jacobs M, Diuguid DL, Furie BC. Randomized prospective trial comparing the native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant therapy. Blood 1990; 75:344-9.
23. Furie B, Furie BC. The molecular basis of blood coagulation. Cell 1988; 53:505-18.
24. Smirnov MD, Safa O, Regan L, et al. A chimeric protein C containing the prothrombin Gla domain exhibits increased anticoagulant activity and altered phospholipid specificity. J Biol Chem 1998; 273: 9031-40.
25. Castellino FJ. Human protein C and activated protein C. Trends Cardiovasc Med 1995; 5:55-62.
26. 2+ prothrombin fragment 1 including the conformation of the gla domain. Biochemistry 1989; 28:6805-10.
27. Banner DW, D'Arcy A, Chene C, et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 1996; 380:41-6.
28. Smirnov M, Rezaie AR, Regan LM, Esmon CT, Esmon NL. The PE dependence of activated protein C function is mediated through the gla-domain. Circulation 1996; 94:1-694(Abstract)
29. Alving BM, Comp PC. Recent advances in understanding clotting and evaluating patients with recurrent thrombosis. Am J Obstet Gynecol 1992; 167: 1184-91.
30. Wattiaux M-J, Herve R, Robert A, Cabane J, Housset B, Imbert J-C. Coumarin-induced skin necrosis associated with acquired protein S deficiency and antiphospholipid antibody syndrome. Arthritis Rheum 1994; 7:1096-100.
31. Ginsberg JS, Demers C, Brill-Edwards P, et al. Acquired free protein S deficiency is associated with antiphospholipid antibodies and increased thrombin generation in patients with systemic lupus erythematosus. Am J Med 1995; 98:379-83.
32. Ames PRJ, Tommasino C, Iannaccone L, Brillante M, Cimino R, Brancaccio V. Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies - A crucial role for acquired free protein S deficiency. Thromb Haemost 1996; 76:190-4.